Centro de Oncología de Precisión

Centro de Oncología de Precisión
Santiago, Región Metropolitana de Santiago, 7560908
Select an option
Open studies
Lung cancer
A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004) - Merck Sharp & Dohme LLCSee more
Lymphoma
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) - CC-99282-NHL-001 - CelgeneSee more
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy